nodes	percent_of_prediction	percent_of_DWPC	metapath
Prochlorperazine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0595	0.0809	CbGbCtD
Prochlorperazine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0559	0.0761	CbGbCtD
Prochlorperazine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0559	0.0761	CbGbCtD
Prochlorperazine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0506	0.0688	CbGbCtD
Prochlorperazine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0506	0.0688	CbGbCtD
Prochlorperazine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0436	0.0594	CbGbCtD
Prochlorperazine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0424	0.0577	CbGbCtD
Prochlorperazine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0383	0.0521	CbGbCtD
Prochlorperazine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0383	0.0521	CbGbCtD
Prochlorperazine—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0378	0.0515	CbGbCtD
Prochlorperazine—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0355	0.0484	CbGbCtD
Prochlorperazine—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0355	0.0484	CbGbCtD
Prochlorperazine—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0321	0.0437	CbGbCtD
Prochlorperazine—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0321	0.0437	CbGbCtD
Prochlorperazine—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0278	0.0378	CbGbCtD
Prochlorperazine—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0269	0.0367	CbGbCtD
Prochlorperazine—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0244	0.0332	CbGbCtD
Prochlorperazine—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0244	0.0332	CbGbCtD
Prochlorperazine—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0234	0.0318	CbGbCtD
Prochlorperazine—DRD2—nerve—acquired immunodeficiency syndrome	0.00152	0.109	CbGeAlD
Prochlorperazine—DRD3—nervous system—acquired immunodeficiency syndrome	0.00081	0.0578	CbGeAlD
Prochlorperazine—DRD3—central nervous system—acquired immunodeficiency syndrome	0.00078	0.0557	CbGeAlD
Prochlorperazine—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000703	0.0502	CbGeAlD
Prochlorperazine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000692	0.0494	CbGeAlD
Prochlorperazine—DRD2—retina—acquired immunodeficiency syndrome	0.000631	0.045	CbGeAlD
Prochlorperazine—DRD3—brain—acquired immunodeficiency syndrome	0.000619	0.0442	CbGeAlD
Prochlorperazine—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000535	0.0382	CbGeAlD
Prochlorperazine—Jaundice—Ritonavir—acquired immunodeficiency syndrome	0.000529	0.00219	CcSEcCtD
Prochlorperazine—Hyperglycaemia—Saquinavir—acquired immunodeficiency syndrome	0.000529	0.00219	CcSEcCtD
Prochlorperazine—Muscle spasms—Zidovudine—acquired immunodeficiency syndrome	0.000525	0.00217	CcSEcCtD
Prochlorperazine—Dry mouth—Stavudine—acquired immunodeficiency syndrome	0.000523	0.00216	CcSEcCtD
Prochlorperazine—Erythema multiforme—Efavirenz—acquired immunodeficiency syndrome	0.000521	0.00215	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Nevirapine—acquired immunodeficiency syndrome	0.00052	0.00215	CcSEcCtD
Prochlorperazine—Oedema peripheral—Delavirdine—acquired immunodeficiency syndrome	0.000519	0.00215	CcSEcCtD
Prochlorperazine—Skin disorder—Nevirapine—acquired immunodeficiency syndrome	0.000516	0.00213	CcSEcCtD
Prochlorperazine—Oedema—Nelfinavir—acquired immunodeficiency syndrome	0.000514	0.00212	CcSEcCtD
Prochlorperazine—Tremor—Zidovudine—acquired immunodeficiency syndrome	0.000511	0.00211	CcSEcCtD
Prochlorperazine—Jaundice—Saquinavir—acquired immunodeficiency syndrome	0.00051	0.00211	CcSEcCtD
Prochlorperazine—Anaphylactic shock—Abacavir—acquired immunodeficiency syndrome	0.000505	0.00209	CcSEcCtD
Prochlorperazine—Oedema—Abacavir—acquired immunodeficiency syndrome	0.000505	0.00209	CcSEcCtD
Prochlorperazine—Hyperglycaemia—Lamivudine—acquired immunodeficiency syndrome	0.000505	0.00208	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Nelfinavir—acquired immunodeficiency syndrome	0.000503	0.00208	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Stavudine—acquired immunodeficiency syndrome	0.000502	0.00207	CcSEcCtD
Prochlorperazine—Infection—Abacavir—acquired immunodeficiency syndrome	0.000502	0.00207	CcSEcCtD
Prochlorperazine—Skin disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000499	0.00206	CcSEcCtD
Prochlorperazine—Angioedema—Zidovudine—acquired immunodeficiency syndrome	0.000499	0.00206	CcSEcCtD
Prochlorperazine—Erythema multiforme—Delavirdine—acquired immunodeficiency syndrome	0.000499	0.00206	CcSEcCtD
Prochlorperazine—Skin disorder—Stavudine—acquired immunodeficiency syndrome	0.000498	0.00206	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Abacavir—acquired immunodeficiency syndrome	0.000494	0.00204	CcSEcCtD
Prochlorperazine—Nervousness—Indinavir—acquired immunodeficiency syndrome	0.000493	0.00204	CcSEcCtD
Prochlorperazine—Arrhythmia—Efavirenz—acquired immunodeficiency syndrome	0.000492	0.00203	CcSEcCtD
Prochlorperazine—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.000491	0.00203	CcSEcCtD
Prochlorperazine—Leukopenia—Zidovudine—acquired immunodeficiency syndrome	0.000489	0.00202	CcSEcCtD
Prochlorperazine—Muscle spasms—Indinavir—acquired immunodeficiency syndrome	0.000488	0.00202	CcSEcCtD
Prochlorperazine—Jaundice—Lamivudine—acquired immunodeficiency syndrome	0.000486	0.00201	CcSEcCtD
Prochlorperazine—Oedema peripheral—Ritonavir—acquired immunodeficiency syndrome	0.00048	0.00198	CcSEcCtD
Prochlorperazine—Erythema—Efavirenz—acquired immunodeficiency syndrome	0.00048	0.00198	CcSEcCtD
Prochlorperazine—Vision blurred—Indinavir—acquired immunodeficiency syndrome	0.000478	0.00198	CcSEcCtD
Prochlorperazine—Cough—Zidovudine—acquired immunodeficiency syndrome	0.000476	0.00197	CcSEcCtD
Prochlorperazine—Tremor—Indinavir—acquired immunodeficiency syndrome	0.000476	0.00197	CcSEcCtD
Prochlorperazine—Convulsion—Zidovudine—acquired immunodeficiency syndrome	0.000473	0.00195	CcSEcCtD
Prochlorperazine—Somnolence—Nevirapine—acquired immunodeficiency syndrome	0.000472	0.00195	CcSEcCtD
Prochlorperazine—Hypotension—Abacavir—acquired immunodeficiency syndrome	0.000472	0.00195	CcSEcCtD
Prochlorperazine—CHRM2—nervous system—acquired immunodeficiency syndrome	0.000467	0.0334	CbGeAlD
Prochlorperazine—Body temperature increased—Didanosine—acquired immunodeficiency syndrome	0.000467	0.00193	CcSEcCtD
Prochlorperazine—Agitation—Indinavir—acquired immunodeficiency syndrome	0.000467	0.00193	CcSEcCtD
Prochlorperazine—Nervousness—Efavirenz—acquired immunodeficiency syndrome	0.000466	0.00193	CcSEcCtD
Prochlorperazine—Agranulocytosis—Lamivudine—acquired immunodeficiency syndrome	0.000465	0.00192	CcSEcCtD
Prochlorperazine—Insomnia—Nelfinavir—acquired immunodeficiency syndrome	0.000465	0.00192	CcSEcCtD
Prochlorperazine—Angioedema—Indinavir—acquired immunodeficiency syndrome	0.000464	0.00192	CcSEcCtD
Prochlorperazine—Insomnia—Stavudine—acquired immunodeficiency syndrome	0.000464	0.00192	CcSEcCtD
Prochlorperazine—Erythema multiforme—Ritonavir—acquired immunodeficiency syndrome	0.000461	0.00191	CcSEcCtD
Prochlorperazine—Erythema—Delavirdine—acquired immunodeficiency syndrome	0.000459	0.0019	CcSEcCtD
Prochlorperazine—Dyspnoea—Nelfinavir—acquired immunodeficiency syndrome	0.000458	0.00189	CcSEcCtD
Prochlorperazine—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.000458	0.00189	CcSEcCtD
Prochlorperazine—Somnolence—Nelfinavir—acquired immunodeficiency syndrome	0.000457	0.00189	CcSEcCtD
Prochlorperazine—Insomnia—Abacavir—acquired immunodeficiency syndrome	0.000457	0.00189	CcSEcCtD
Prochlorperazine—Somnolence—Stavudine—acquired immunodeficiency syndrome	0.000456	0.00188	CcSEcCtD
Prochlorperazine—Vision blurred—Efavirenz—acquired immunodeficiency syndrome	0.000452	0.00187	CcSEcCtD
Prochlorperazine—HTR2C—nervous system—acquired immunodeficiency syndrome	0.00045	0.0322	CbGeAlD
Prochlorperazine—Dyspnoea—Abacavir—acquired immunodeficiency syndrome	0.00045	0.00186	CcSEcCtD
Prochlorperazine—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.00045	0.0321	CbGeAlD
Prochlorperazine—Tremor—Efavirenz—acquired immunodeficiency syndrome	0.000449	0.00186	CcSEcCtD
Prochlorperazine—Nervousness—Delavirdine—acquired immunodeficiency syndrome	0.000446	0.00184	CcSEcCtD
Prochlorperazine—Anaphylactic shock—Zidovudine—acquired immunodeficiency syndrome	0.000446	0.00184	CcSEcCtD
Prochlorperazine—Oedema—Zidovudine—acquired immunodeficiency syndrome	0.000446	0.00184	CcSEcCtD
Prochlorperazine—Erythema multiforme—Saquinavir—acquired immunodeficiency syndrome	0.000444	0.00183	CcSEcCtD
Prochlorperazine—Cough—Indinavir—acquired immunodeficiency syndrome	0.000443	0.00183	CcSEcCtD
Prochlorperazine—Muscle spasms—Delavirdine—acquired immunodeficiency syndrome	0.000441	0.00182	CcSEcCtD
Prochlorperazine—Agitation—Efavirenz—acquired immunodeficiency syndrome	0.000441	0.00182	CcSEcCtD
Prochlorperazine—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000438	0.00181	CcSEcCtD
Prochlorperazine—Angioedema—Efavirenz—acquired immunodeficiency syndrome	0.000438	0.00181	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Zidovudine—acquired immunodeficiency syndrome	0.000436	0.0018	CcSEcCtD
Prochlorperazine—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.000435	0.0018	CcSEcCtD
Prochlorperazine—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000434	0.031	CbGeAlD
Prochlorperazine—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000433	0.00179	CcSEcCtD
Prochlorperazine—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.000433	0.00179	CcSEcCtD
Prochlorperazine—Tremor—Delavirdine—acquired immunodeficiency syndrome	0.00043	0.00178	CcSEcCtD
Prochlorperazine—Erythema multiforme—Lamivudine—acquired immunodeficiency syndrome	0.000423	0.00175	CcSEcCtD
Prochlorperazine—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.000423	0.00175	CcSEcCtD
Prochlorperazine—Agitation—Delavirdine—acquired immunodeficiency syndrome	0.000422	0.00174	CcSEcCtD
Prochlorperazine—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.000422	0.00174	CcSEcCtD
Prochlorperazine—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.00042	0.00173	CcSEcCtD
Prochlorperazine—Angioedema—Delavirdine—acquired immunodeficiency syndrome	0.000419	0.00173	CcSEcCtD
Prochlorperazine—Cough—Efavirenz—acquired immunodeficiency syndrome	0.000419	0.00173	CcSEcCtD
Prochlorperazine—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000418	0.00173	CcSEcCtD
Prochlorperazine—Convulsion—Efavirenz—acquired immunodeficiency syndrome	0.000416	0.00172	CcSEcCtD
Prochlorperazine—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.000414	0.00171	CcSEcCtD
Prochlorperazine—Oedema—Indinavir—acquired immunodeficiency syndrome	0.000414	0.00171	CcSEcCtD
Prochlorperazine—Nervousness—Ritonavir—acquired immunodeficiency syndrome	0.000412	0.0017	CcSEcCtD
Prochlorperazine—Leukopenia—Delavirdine—acquired immunodeficiency syndrome	0.000411	0.0017	CcSEcCtD
Prochlorperazine—Erythema—Saquinavir—acquired immunodeficiency syndrome	0.000409	0.00169	CcSEcCtD
Prochlorperazine—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.000408	0.00169	CcSEcCtD
Prochlorperazine—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000408	0.00169	CcSEcCtD
Prochlorperazine—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.000408	0.00169	CcSEcCtD
Prochlorperazine—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000408	0.00169	CcSEcCtD
Prochlorperazine—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.000407	0.00168	CcSEcCtD
Prochlorperazine—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000406	0.00168	CcSEcCtD
Prochlorperazine—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000406	0.00168	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Indinavir—acquired immunodeficiency syndrome	0.000406	0.00168	CcSEcCtD
Prochlorperazine—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000405	0.00167	CcSEcCtD
Prochlorperazine—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.000403	0.00167	CcSEcCtD
Prochlorperazine—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000402	0.00166	CcSEcCtD
Prochlorperazine—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000401	0.00166	CcSEcCtD
Prochlorperazine—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000401	0.00166	CcSEcCtD
Prochlorperazine—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.0004	0.00165	CcSEcCtD
Prochlorperazine—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000399	0.00165	CcSEcCtD
Prochlorperazine—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000399	0.00165	CcSEcCtD
Prochlorperazine—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000398	0.00164	CcSEcCtD
Prochlorperazine—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000397	0.00164	CcSEcCtD
Prochlorperazine—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000396	0.00164	CcSEcCtD
Prochlorperazine—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000393	0.00162	CcSEcCtD
Prochlorperazine—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000391	0.00162	CcSEcCtD
Prochlorperazine—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.00039	0.00161	CcSEcCtD
Prochlorperazine—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.00039	0.00161	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000383	0.00158	CcSEcCtD
Prochlorperazine—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000383	0.00158	CcSEcCtD
Prochlorperazine—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000382	0.00158	CcSEcCtD
Prochlorperazine—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000381	0.00157	CcSEcCtD
Prochlorperazine—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.00038	0.00157	CcSEcCtD
Prochlorperazine—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.00038	0.00157	CcSEcCtD
Prochlorperazine—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000379	0.00157	CcSEcCtD
Prochlorperazine—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.000379	0.00156	CcSEcCtD
Prochlorperazine—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000378	0.00156	CcSEcCtD
Prochlorperazine—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000376	0.00155	CcSEcCtD
Prochlorperazine—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000375	0.00155	CcSEcCtD
Prochlorperazine—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000375	0.00155	CcSEcCtD
Prochlorperazine—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000375	0.00155	CcSEcCtD
Prochlorperazine—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000375	0.00155	CcSEcCtD
Prochlorperazine—Rash—Didanosine—acquired immunodeficiency syndrome	0.000372	0.00154	CcSEcCtD
Prochlorperazine—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000372	0.00154	CcSEcCtD
Prochlorperazine—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000372	0.00154	CcSEcCtD
Prochlorperazine—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000372	0.00154	CcSEcCtD
Prochlorperazine—Cough—Ritonavir—acquired immunodeficiency syndrome	0.00037	0.00153	CcSEcCtD
Prochlorperazine—DRD2—lung—acquired immunodeficiency syndrome	0.00037	0.0264	CbGeAlD
Prochlorperazine—Headache—Didanosine—acquired immunodeficiency syndrome	0.00037	0.00153	CcSEcCtD
Prochlorperazine—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000369	0.00153	CcSEcCtD
Prochlorperazine—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000368	0.00152	CcSEcCtD
Prochlorperazine—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000368	0.00152	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000367	0.00152	CcSEcCtD
Prochlorperazine—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.000366	0.00151	CcSEcCtD
Prochlorperazine—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000365	0.00151	CcSEcCtD
Prochlorperazine—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000364	0.0015	CcSEcCtD
Prochlorperazine—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000364	0.0015	CcSEcCtD
Prochlorperazine—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000363	0.0015	CcSEcCtD
Prochlorperazine—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000357	0.00148	CcSEcCtD
Prochlorperazine—CHRM2—brain—acquired immunodeficiency syndrome	0.000357	0.0255	CbGeAlD
Prochlorperazine—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000356	0.00147	CcSEcCtD
Prochlorperazine—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000356	0.00147	CcSEcCtD
Prochlorperazine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000354	0.00146	CcSEcCtD
Prochlorperazine—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000354	0.00146	CcSEcCtD
Prochlorperazine—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000354	0.00146	CcSEcCtD
Prochlorperazine—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000354	0.00146	CcSEcCtD
Prochlorperazine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000353	0.00146	CcSEcCtD
Prochlorperazine—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000352	0.00146	CcSEcCtD
Prochlorperazine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.00035	0.00145	CcSEcCtD
Prochlorperazine—HRH1—digestive system—acquired immunodeficiency syndrome	0.00035	0.025	CbGeAlD
Prochlorperazine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000349	0.00144	CcSEcCtD
Prochlorperazine—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.000349	0.00144	CcSEcCtD
Prochlorperazine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000348	0.00144	CcSEcCtD
Prochlorperazine—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000346	0.00143	CcSEcCtD
Prochlorperazine—HTR2C—brain—acquired immunodeficiency syndrome	0.000344	0.0246	CbGeAlD
Prochlorperazine—DRD2—nervous system—acquired immunodeficiency syndrome	0.000343	0.0245	CbGeAlD
Prochlorperazine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.00034	0.00141	CcSEcCtD
Prochlorperazine—Cough—Lamivudine—acquired immunodeficiency syndrome	0.00034	0.00141	CcSEcCtD
Prochlorperazine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00034	0.00141	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000339	0.0014	CcSEcCtD
Prochlorperazine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000339	0.0014	CcSEcCtD
Prochlorperazine—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000339	0.0014	CcSEcCtD
Prochlorperazine—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000338	0.0014	CcSEcCtD
Prochlorperazine—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000336	0.00139	CcSEcCtD
Prochlorperazine—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000335	0.00138	CcSEcCtD
Prochlorperazine—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000335	0.00138	CcSEcCtD
Prochlorperazine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000334	0.00138	CcSEcCtD
Prochlorperazine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000334	0.00138	CcSEcCtD
Prochlorperazine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000334	0.00138	CcSEcCtD
Prochlorperazine—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000333	0.00138	CcSEcCtD
Prochlorperazine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000333	0.00138	CcSEcCtD
Prochlorperazine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000333	0.00137	CcSEcCtD
Prochlorperazine—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000331	0.00137	CcSEcCtD
Prochlorperazine—DRD2—central nervous system—acquired immunodeficiency syndrome	0.00033	0.0235	CbGeAlD
Prochlorperazine—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000329	0.00136	CcSEcCtD
Prochlorperazine—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000328	0.00135	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000326	0.00135	CcSEcCtD
Prochlorperazine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000324	0.00134	CcSEcCtD
Prochlorperazine—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000324	0.00134	CcSEcCtD
Prochlorperazine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000324	0.00134	CcSEcCtD
Prochlorperazine—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000324	0.00134	CcSEcCtD
Prochlorperazine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000324	0.00134	CcSEcCtD
Prochlorperazine—Rash—Stavudine—acquired immunodeficiency syndrome	0.000323	0.00134	CcSEcCtD
Prochlorperazine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000323	0.00133	CcSEcCtD
Prochlorperazine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000322	0.00133	CcSEcCtD
Prochlorperazine—Headache—Stavudine—acquired immunodeficiency syndrome	0.000321	0.00133	CcSEcCtD
Prochlorperazine—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.00032	0.00132	CcSEcCtD
Prochlorperazine—Rash—Abacavir—acquired immunodeficiency syndrome	0.000318	0.00132	CcSEcCtD
Prochlorperazine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000318	0.00131	CcSEcCtD
Prochlorperazine—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000318	0.00131	CcSEcCtD
Prochlorperazine—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000318	0.00131	CcSEcCtD
Prochlorperazine—Headache—Abacavir—acquired immunodeficiency syndrome	0.000316	0.00131	CcSEcCtD
Prochlorperazine—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000316	0.00131	CcSEcCtD
Prochlorperazine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000315	0.0013	CcSEcCtD
Prochlorperazine—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000313	0.00129	CcSEcCtD
Prochlorperazine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000312	0.00129	CcSEcCtD
Prochlorperazine—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000311	0.00129	CcSEcCtD
Prochlorperazine—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000311	0.00129	CcSEcCtD
Prochlorperazine—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000309	0.00128	CcSEcCtD
Prochlorperazine—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000309	0.00128	CcSEcCtD
Prochlorperazine—HRH1—vagina—acquired immunodeficiency syndrome	0.000309	0.0221	CbGeAlD
Prochlorperazine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000309	0.00128	CcSEcCtD
Prochlorperazine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000308	0.00127	CcSEcCtD
Prochlorperazine—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000305	0.00126	CcSEcCtD
Prochlorperazine—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000302	0.00125	CcSEcCtD
Prochlorperazine—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000298	0.00123	CcSEcCtD
Prochlorperazine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000297	0.00123	CcSEcCtD
Prochlorperazine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000297	0.00123	CcSEcCtD
Prochlorperazine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000296	0.00122	CcSEcCtD
Prochlorperazine—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000296	0.00122	CcSEcCtD
Prochlorperazine—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000296	0.00122	CcSEcCtD
Prochlorperazine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000295	0.00122	CcSEcCtD
Prochlorperazine—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000293	0.00121	CcSEcCtD
Prochlorperazine—HRH1—lung—acquired immunodeficiency syndrome	0.000292	0.0209	CbGeAlD
Prochlorperazine—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000288	0.00119	CcSEcCtD
Prochlorperazine—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000288	0.00119	CcSEcCtD
Prochlorperazine—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000285	0.00118	CcSEcCtD
Prochlorperazine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000284	0.00117	CcSEcCtD
Prochlorperazine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000283	0.00117	CcSEcCtD
Prochlorperazine—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000281	0.00116	CcSEcCtD
Prochlorperazine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000281	0.00116	CcSEcCtD
Prochlorperazine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000279	0.00115	CcSEcCtD
Prochlorperazine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000277	0.00114	CcSEcCtD
Prochlorperazine—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000276	0.00114	CcSEcCtD
Prochlorperazine—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000275	0.00114	CcSEcCtD
Prochlorperazine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000274	0.00113	CcSEcCtD
Prochlorperazine—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000274	0.00113	CcSEcCtD
Prochlorperazine—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000272	0.00112	CcSEcCtD
Prochlorperazine—HRH1—nervous system—acquired immunodeficiency syndrome	0.000271	0.0193	CbGeAlD
Prochlorperazine—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.00027	0.0193	CbGeAlD
Prochlorperazine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000266	0.019	CbGeAlD
Prochlorperazine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000265	0.0011	CcSEcCtD
Prochlorperazine—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000265	0.00109	CcSEcCtD
Prochlorperazine—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000264	0.00109	CcSEcCtD
Prochlorperazine—DRD2—brain—acquired immunodeficiency syndrome	0.000262	0.0187	CbGeAlD
Prochlorperazine—Rash—Indinavir—acquired immunodeficiency syndrome	0.000261	0.00108	CcSEcCtD
Prochlorperazine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000261	0.00108	CcSEcCtD
Prochlorperazine—HRH1—central nervous system—acquired immunodeficiency syndrome	0.00026	0.0186	CbGeAlD
Prochlorperazine—Headache—Indinavir—acquired immunodeficiency syndrome	0.00026	0.00107	CcSEcCtD
Prochlorperazine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000259	0.00107	CcSEcCtD
Prochlorperazine—CYP3A4—blood—acquired immunodeficiency syndrome	0.000258	0.0184	CbGeAlD
Prochlorperazine—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000255	0.00105	CcSEcCtD
Prochlorperazine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000254	0.0181	CbGeAlD
Prochlorperazine—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000253	0.00104	CcSEcCtD
Prochlorperazine—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000251	0.00104	CcSEcCtD
Prochlorperazine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000248	0.00102	CcSEcCtD
Prochlorperazine—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000247	0.00102	CcSEcCtD
Prochlorperazine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000247	0.00102	CcSEcCtD
Prochlorperazine—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000246	0.00102	CcSEcCtD
Prochlorperazine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000245	0.00101	CcSEcCtD
Prochlorperazine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000245	0.00101	CcSEcCtD
Prochlorperazine—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000236	0.000976	CcSEcCtD
Prochlorperazine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000236	0.000975	CcSEcCtD
Prochlorperazine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000236	0.000975	CcSEcCtD
Prochlorperazine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000235	0.00097	CcSEcCtD
Prochlorperazine—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000234	0.000968	CcSEcCtD
Prochlorperazine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000229	0.000947	CcSEcCtD
Prochlorperazine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000225	0.00093	CcSEcCtD
Prochlorperazine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00022	0.000911	CcSEcCtD
Prochlorperazine—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000218	0.000903	CcSEcCtD
Prochlorperazine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000218	0.000902	CcSEcCtD
Prochlorperazine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000217	0.000897	CcSEcCtD
Prochlorperazine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00021	0.000869	CcSEcCtD
Prochlorperazine—Rash—Saquinavir—acquired immunodeficiency syndrome	0.00021	0.000869	CcSEcCtD
Prochlorperazine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.00021	0.000868	CcSEcCtD
Prochlorperazine—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000209	0.0149	CbGeAlD
Prochlorperazine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000209	0.000863	CcSEcCtD
Prochlorperazine—HRH1—brain—acquired immunodeficiency syndrome	0.000207	0.0148	CbGeAlD
Prochlorperazine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000206	0.0147	CbGeAlD
Prochlorperazine—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000201	0.0144	CbGeAlD
Prochlorperazine—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000201	0.000829	CcSEcCtD
Prochlorperazine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.0002	0.000828	CcSEcCtD
Prochlorperazine—HRH1—lymph node—acquired immunodeficiency syndrome	0.0002	0.0143	CbGeAlD
Prochlorperazine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000199	0.000823	CcSEcCtD
Prochlorperazine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000198	0.0141	CbGeAlD
Prochlorperazine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000157	0.0112	CbGeAlD
Prochlorperazine—Acepromazine—ALB—acquired immunodeficiency syndrome	8.8e-05	0.193	CrCbGaD
Prochlorperazine—Thioproperazine—ALB—acquired immunodeficiency syndrome	8.6e-05	0.189	CrCbGaD
Prochlorperazine—Thiothixene—ALB—acquired immunodeficiency syndrome	8.46e-05	0.186	CrCbGaD
Prochlorperazine—Pipotiazine—ALB—acquired immunodeficiency syndrome	8.46e-05	0.186	CrCbGaD
Prochlorperazine—Clomipramine—ALB—acquired immunodeficiency syndrome	6.69e-05	0.147	CrCbGaD
Prochlorperazine—Chlorpromazine—ALB—acquired immunodeficiency syndrome	4.59e-05	0.101	CrCbGaD
Prochlorperazine—CHRM2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	4.39e-05	0.00504	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	4.37e-05	0.00502	CbGpPWpGaD
Prochlorperazine—CHRM2—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	4.34e-05	0.00499	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	4.3e-05	0.00494	CbGpPWpGaD
Prochlorperazine—DRD2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	4.27e-05	0.00491	CbGpPWpGaD
Prochlorperazine—DRD2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	4.27e-05	0.00491	CbGpPWpGaD
Prochlorperazine—DRD3—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	4.25e-05	0.00488	CbGpPWpGaD
Prochlorperazine—DRD2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.22e-05	0.00484	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.17e-05	0.00479	CbGpPWpGaD
Prochlorperazine—HRH1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.14e-05	0.00476	CbGpPWpGaD
Prochlorperazine—CHRM2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	4.13e-05	0.00474	CbGpPWpGaD
Prochlorperazine—CHRM2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	4.13e-05	0.00474	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.09e-05	0.0047	CbGpPWpGaD
Prochlorperazine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	4.09e-05	0.0047	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.07e-05	0.00468	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	4.03e-05	0.00463	CbGpPWpGaD
Prochlorperazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	3.99e-05	0.00459	CbGpPWpGaD
Prochlorperazine—DRD3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.97e-05	0.00457	CbGpPWpGaD
Prochlorperazine—DRD2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	3.96e-05	0.00455	CbGpPWpGaD
Prochlorperazine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	3.92e-05	0.00451	CbGpPWpGaD
Prochlorperazine—HRH1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	3.89e-05	0.00447	CbGpPWpGaD
Prochlorperazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	3.86e-05	0.00443	CbGpPWpGaD
Prochlorperazine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.85e-05	0.00442	CbGpPWpGaD
Prochlorperazine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.85e-05	0.00442	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	3.83e-05	0.0044	CbGpPWpGaD
Prochlorperazine—DRD3—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	3.83e-05	0.0044	CbGpPWpGaD
Prochlorperazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.61e-05	0.00415	CbGpPWpGaD
Prochlorperazine—DRD3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.59e-05	0.00413	CbGpPWpGaD
Prochlorperazine—DRD3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.55e-05	0.00408	CbGpPWpGaD
Prochlorperazine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.55e-05	0.00408	CbGpPWpGaD
Prochlorperazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.49e-05	0.00401	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.45e-05	0.00396	CbGpPWpGaD
Prochlorperazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.4e-05	0.0039	CbGpPWpGaD
Prochlorperazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.4e-05	0.0039	CbGpPWpGaD
Prochlorperazine—DRD3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	3.38e-05	0.00388	CbGpPWpGaD
Prochlorperazine—DRD3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	3.38e-05	0.00388	CbGpPWpGaD
Prochlorperazine—DRD3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	3.38e-05	0.00388	CbGpPWpGaD
Prochlorperazine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.33e-05	0.00383	CbGpPWpGaD
Prochlorperazine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.33e-05	0.00383	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	3.3e-05	0.00379	CbGpPWpGaD
Prochlorperazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.28e-05	0.00377	CbGpPWpGaD
Prochlorperazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.28e-05	0.00377	CbGpPWpGaD
Prochlorperazine—DRD2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.25e-05	0.00373	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	3.22e-05	0.0037	CbGpPWpGaD
Prochlorperazine—CHRM2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.14e-05	0.00361	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	3.12e-05	0.00358	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	3.08e-05	0.00354	CbGpPWpGaD
Prochlorperazine—DRD3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	3.04e-05	0.0035	CbGpPWpGaD
Prochlorperazine—DRD2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	3.04e-05	0.00349	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	2.99e-05	0.00343	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.99e-05	0.00343	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	2.94e-05	0.00338	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.93e-05	0.00337	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.93e-05	0.00337	CbGpPWpGaD
Prochlorperazine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.93e-05	0.00336	CbGpPWpGaD
Prochlorperazine—DRD2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	2.93e-05	0.00336	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.86e-05	0.00329	CbGpPWpGaD
Prochlorperazine—CHRM2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	2.83e-05	0.00325	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.79e-05	0.00321	CbGpPWpGaD
Prochlorperazine—DRD2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.75e-05	0.00316	CbGpPWpGaD
Prochlorperazine—DRD2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.72e-05	0.00312	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.7e-05	0.0031	CbGpPWpGaD
Prochlorperazine—HRH1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.67e-05	0.00306	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.66e-05	0.00305	CbGpPWpGaD
Prochlorperazine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.64e-05	0.00303	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.62e-05	0.00302	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.59e-05	0.00297	CbGpPWpGaD
Prochlorperazine—DRD2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.59e-05	0.00297	CbGpPWpGaD
Prochlorperazine—DRD2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.59e-05	0.00297	CbGpPWpGaD
Prochlorperazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.58e-05	0.00297	CbGpPWpGaD
Prochlorperazine—DRD3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.57e-05	0.00295	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.54e-05	0.00292	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.54e-05	0.00292	CbGpPWpGaD
Prochlorperazine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.54e-05	0.00291	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.53e-05	0.0029	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.5e-05	0.00287	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.5e-05	0.00287	CbGpPWpGaD
Prochlorperazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.5e-05	0.00287	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.48e-05	0.00285	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.46e-05	0.00283	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.44e-05	0.0028	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.42e-05	0.00278	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.38e-05	0.00273	CbGpPWpGaD
Prochlorperazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.33e-05	0.00267	CbGpPWpGaD
Prochlorperazine—DRD3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.32e-05	0.00266	CbGpPWpGaD
Prochlorperazine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.29e-05	0.00263	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.28e-05	0.00263	CbGpPWpGaD
Prochlorperazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.25e-05	0.00258	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.24e-05	0.00258	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	2.23e-05	0.00256	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.21e-05	0.00254	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.04e-05	0.00234	CbGpPWpGaD
Prochlorperazine—DRD3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	2.03e-05	0.00233	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	2.01e-05	0.00231	CbGpPWpGaD
Prochlorperazine—DRD2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.97e-05	0.00226	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.95e-05	0.00224	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.95e-05	0.00224	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.93e-05	0.00222	CbGpPWpGaD
Prochlorperazine—DRD3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.91e-05	0.00219	CbGpPWpGaD
Prochlorperazine—DRD3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.91e-05	0.00219	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.9e-05	0.00218	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.84e-05	0.00212	CbGpPWpGaD
Prochlorperazine—DRD2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.77e-05	0.00204	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.77e-05	0.00203	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.76e-05	0.00203	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.76e-05	0.00202	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.74e-05	0.002	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.73e-05	0.00199	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.73e-05	0.00199	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.71e-05	0.00197	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.69e-05	0.00194	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.69e-05	0.00194	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.66e-05	0.0019	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.66e-05	0.0019	CbGpPWpGaD
Prochlorperazine—CHRM2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	1.65e-05	0.0019	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.6e-05	0.00184	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.56e-05	0.00179	CbGpPWpGaD
Prochlorperazine—DRD2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.55e-05	0.00179	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.53e-05	0.00176	CbGpPWpGaD
Prochlorperazine—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.53e-05	0.00176	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.53e-05	0.00176	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.53e-05	0.00175	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.51e-05	0.00173	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.5e-05	0.00173	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.5e-05	0.00173	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.5e-05	0.00173	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.49e-05	0.00171	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.49e-05	0.00171	CbGpPWpGaD
Prochlorperazine—DRD3—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.47e-05	0.00169	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.47e-05	0.00168	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.47e-05	0.00168	CbGpPWpGaD
Prochlorperazine—DRD2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.46e-05	0.00168	CbGpPWpGaD
Prochlorperazine—DRD2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.46e-05	0.00168	CbGpPWpGaD
Prochlorperazine—DRD3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.45e-05	0.00167	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.44e-05	0.00166	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.44e-05	0.00166	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.43e-05	0.00165	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.43e-05	0.00165	CbGpPWpGaD
Prochlorperazine—DRD3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.43e-05	0.00164	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.41e-05	0.00162	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.41e-05	0.00162	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.41e-05	0.00162	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.39e-05	0.00159	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.36e-05	0.00157	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.35e-05	0.00155	CbGpPWpGaD
Prochlorperazine—CHRM2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	1.33e-05	0.00153	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.33e-05	0.00152	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.33e-05	0.00152	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.33e-05	0.00152	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.32e-05	0.00152	CbGpPWpGaD
Prochlorperazine—DRD3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.31e-05	0.0015	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.3e-05	0.0015	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.3e-05	0.0015	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.3e-05	0.0015	CbGpPWpGaD
Prochlorperazine—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.3e-05	0.0015	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.3e-05	0.00149	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.28e-05	0.00147	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.28e-05	0.00147	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.26e-05	0.00145	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.24e-05	0.00143	CbGpPWpGaD
Prochlorperazine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.21e-05	0.00139	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.2e-05	0.00138	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.19e-05	0.00137	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.14e-05	0.00131	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1.13e-05	0.0013	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.13e-05	0.00129	CbGpPWpGaD
Prochlorperazine—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.13e-05	0.00129	CbGpPWpGaD
Prochlorperazine—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.11e-05	0.00128	CbGpPWpGaD
Prochlorperazine—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.1e-05	0.00126	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.09e-05	0.00125	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.09e-05	0.00125	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.08e-05	0.00124	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.07e-05	0.00123	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.06e-05	0.00122	CbGpPWpGaD
Prochlorperazine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	1.05e-05	0.0012	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.04e-05	0.0012	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.03e-05	0.00118	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.02e-05	0.00118	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.02e-05	0.00118	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.01e-05	0.00116	CbGpPWpGaD
Prochlorperazine—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	1e-05	0.00115	CbGpPWpGaD
Prochlorperazine—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	1e-05	0.00115	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	9.94e-06	0.00114	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	9.91e-06	0.00114	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	9.83e-06	0.00113	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	9.76e-06	0.00112	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	9.75e-06	0.00112	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	9.68e-06	0.00111	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	9.61e-06	0.0011	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.45e-06	0.00109	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.22e-06	0.00106	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.1e-06	0.00105	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.05e-06	0.00104	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.93e-06	0.00103	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.91e-06	0.00102	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.88e-06	0.00102	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.88e-06	0.00102	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.79e-06	0.00101	CbGpPWpGaD
Prochlorperazine—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	8.51e-06	0.000978	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.34e-06	0.000958	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.19e-06	0.000941	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.06e-06	0.000926	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.84e-06	0.000901	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.84e-06	0.000901	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.79e-06	0.000896	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.7e-06	0.000884	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.7e-06	0.000884	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.68e-06	0.000882	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.57e-06	0.00087	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.57e-06	0.00087	CbGpPWpGaD
Prochlorperazine—DRD3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.56e-06	0.000869	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.02e-06	0.000807	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.87e-06	0.000789	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.76e-06	0.000777	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.66e-06	0.000765	CbGpPWpGaD
Prochlorperazine—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.56e-06	0.000754	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.09e-06	0.0007	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.96e-06	0.000685	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.95e-06	0.000684	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.87e-06	0.000675	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.86e-06	0.000673	CbGpPWpGaD
Prochlorperazine—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.79e-06	0.000665	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.77e-06	0.000663	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.76e-06	0.000662	CbGpPWpGaD
Prochlorperazine—HRH1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.68e-06	0.000653	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.68e-06	0.000652	CbGpPWpGaD
Prochlorperazine—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.59e-06	0.000642	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.37e-06	0.000617	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.28e-06	0.000606	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.26e-06	0.000604	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.19e-06	0.000597	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.16e-06	0.000593	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.08e-06	0.000583	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.06e-06	0.000466	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.04e-06	0.000464	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.52e-06	0.000404	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.5e-06	0.000402	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.1e-06	0.000357	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.09e-06	0.000355	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.05e-06	0.00035	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.03e-06	0.000349	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3e-06	0.000345	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.98e-06	0.000343	CbGpPWpGaD
Prochlorperazine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	2.67e-06	0.000307	CbGpPWpGaD
Prochlorperazine—DRD3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.38e-06	0.000274	CbGpPWpGaD
Prochlorperazine—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.07e-06	0.000238	CbGpPWpGaD
Prochlorperazine—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.82e-06	0.00021	CbGpPWpGaD
Prochlorperazine—HRH1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.79e-06	0.000206	CbGpPWpGaD
Prochlorperazine—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.76e-06	0.000203	CbGpPWpGaD
Prochlorperazine—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.75e-06	0.000201	CbGpPWpGaD
